Literature DB >> 25613671

Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.

M K A Basra1, M S Salek, L Camilleri, R Sturkey, A Y Finlay.   

Abstract

AIMS: To determine the minimal clinically important difference (MCID) of the Dermatology Life Quality Index (DLQI) and its responsiveness to change in inflammatory skin diseases.
METHODS: A longitudinal study: at stage 1, patients completed the DLQI and a disease severity global question; at stage 2, a global rating of change in quality of life (QoL; Global Rating of Change Questionnaire, GRCQ) was added and used as an anchor to measure the MCID of the DLQI.
RESULTS: 192 patients completed stage 1 and 107 completed stage 2. The mean DLQI score at stage 1 was 9.8 and 7.4 at stage 2 with a mean change of 2.4 (p < 0.0001). 31 patients experienced a 'small change' in their QoL (±3 and ±2) on the GRCQ. The mean corresponding change in DLQI scores was 3.3, which is regarded as the approximate MCID.
CONCLUSIONS: Previous estimates of the MCID of the DLQI have varied from 3 to 5. Although this study demonstrated a MCID of 3.3, we recommend that the MCID in inflammatory skin diseases should be 4.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25613671     DOI: 10.1159/000365390

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  71 in total

1.  Discrepancies between the Dermatology Life Quality Index and utility scores.

Authors:  Fanni Rencz; Petra Baji; László Gulácsi; Sarolta Kárpáti; Márta Péntek; Adrienn Katalin Poór; Valentin Brodszky
Journal:  Qual Life Res       Date:  2015-12-18       Impact factor: 4.147

2.  [56-year-old male with erythematous, excoriated papules and nodules on the extremities, shoulders and buttocks : Preparation for the specialist examination: part 12].

Authors:  Vincent Hoffmann; Claudia Zeidler; Sonja Ständer
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

3.  Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review.

Authors:  Asma Amir Ali; Elizabeth K Seng; Afsaneh Alavi; Michelle A Lowes
Journal:  J Am Acad Dermatol       Date:  2019-05-29       Impact factor: 11.527

4.  Responsiveness to Change and Establishment of the Minimal Clinically Important Difference for the Cutaneous Sarcoidosis Activity and Morphology Instrument.

Authors:  Megan H Noe; Joel M Gelfand; Joshua S Bryer; Sarah N Price; Marc A Judson; Misha Rosenbach
Journal:  JAMA Dermatol       Date:  2020-01-01       Impact factor: 10.282

5.  Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.

Authors:  S Ahmed; S Chakka; J Concha; R Krain; R Feng; V P Werth
Journal:  Br J Dermatol       Date:  2019-09-08       Impact factor: 9.302

Review 6.  Emollients and moisturisers for eczema.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Robin Christensen; Adriana Lavrijsen; Bernd WM Arents
Journal:  Cochrane Database Syst Rev       Date:  2017-02-06

7.  The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.

Authors:  Claire R Stewart; Leah Algu; Rakhshan Kamran; Cameron F Leveille; Khizar Abid; Charlene Rae; Shari R Lipner
Journal:  Skin Appendage Disord       Date:  2021-01-22

8.  Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.

Authors:  D O'Kane; L Davis; M Ardern-Jones; P Laws; L Shaw; M Cork; S Velangi; H L Cooper; R Hudson; A B Smith; R Rout
Journal:  Ulster Med J       Date:  2021-07-08

Review 9.  Quality of Life in Hidradenitis Suppurativa: An Update.

Authors:  Pavel V Chernyshov; Andrew Y Finlay; Lucia Tomas-Aragones; Francoise Poot; Francesca Sampogna; Servando E Marron; Sergey V Zemskov; Damiano Abeni; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis
Journal:  Int J Environ Res Public Health       Date:  2021-06-06       Impact factor: 3.390

10.  Determining the Minimal Important Difference for the Wound-QoL Questionnaire.

Authors:  Janine Topp; Christine Blome; Matthias Augustin; Nicole Mohr; Eike Sebastian Debus; Holger Diener; Rachel Sommer
Journal:  Patient Prefer Adherence       Date:  2021-07-14       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.